Accelerate Diagnostics Diluted EPS
The Diluted Earnings per Share of Accelerate Diagnostics (AXDX) as of Sep 13, 2026 is -2.15 USD. In the previous year, Diluted Earnings per Share was -4.94 USD — a change of -56.51% (higher).
Get this data via API
Financial Data API
Diluted EPS
-2.15USD
YoY
-56.51%
Last updated:
The Accelerate Diagnostics Diluted EPS history
3 Years
10 Years
25 Years
Max
| YEAR | Diluted EPS | YoY |
|---|---|---|
| -2.15USD | -56.51% | |
| -4.94USD | -51.22% | |
| -10.12USD | -19.57% | |
| -12.59USD | -9.85% | |
| -13.96USD | -9.72% | |
| -15.47USD | -4.57% | |
| -16.21USD | +39.38% | |
| -11.63USD | -10.16% | |
| -12.94USD | +28.02% | |
| -10.11USD | +42.60% | |
| -7.09USD | +74.45% | |
| -4.06USD | -4.63% | |
| -4.26USD | +1,114.25% | |
| -0.35USD | -156.93% | |
| 0.62USD | -188.28% | |
| -0.70USD | -58.19% | |
| -1.67USD | -13.48% | |
| -1.93USD | -36.51% | |
| -3.04USD | +44.87% | |
| -2.10USD | +129.90% | |
| -0.91USD | -36.89% | |
| -1.45USD | +201.90% | |
| -0.48USD | -76.21% | |
| -2.01USD | +69.56% | |
| -1.19USD | -1,455.26% | |
| 0.09USD | -97.53% | |
| 3.54USD | +195.22% | |
| 1.20USD | -40.08% | |
| 2.00USD | +186.08% | |
| 0.70USD | -245.83% | |
| -0.48USD | +860.00% | |
| -0.05USD | — |
Accelerate Diagnostics Stock analysis
Frequently Asked Questions about Accelerate Diagnostics stock
Diluted Earnings per Share of Accelerate Diagnostics is -2.15 USD in 2026.
Diluted Earnings per Share of Accelerate Diagnostics changed from -4.94 USD to -2.15 USD, representing a -56.51% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Diluted Earnings per Share Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.
Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.
Income Statement — Accelerate Diagnostics
All Key Metrics — Accelerate Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth